Bank Of America Corp Immunic, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Immunic, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 19,673 shares of IMUX stock, worth $21,246. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,673

Previous 22,416 12.24%

Holding current value

$21,246

Previous $24,000 33.33%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.08 - $1.95 $2,962 - $5,348	-2,743 Reduced 12.24%	19,673 $32,000
Q2 2024 Aug 14, 2024	SELL	$0.98 - $1.44 $94,275 - $138,526	-96,199 Reduced 81.1%	22,416 $24,000
Q1 2024 May 15, 2024	BUY	$1.14 - $1.53 $36,179 - $48,556	31,736 Added 36.53%	118,615 $156,000
Q4 2023 Feb 14, 2024	SELL	$0.97 - $1.6 $64,769 - $106,836	-66,773 Reduced 43.46%	86,879 $130,000
Q2 2023 Aug 14, 2023	BUY	$1.33 - $2.51 $83,948 - $158,428	63,119 Added 69.72%	153,652 $385,000
Q1 2023 May 12, 2023	SELL	$1.35 - $2.87 $453,760 - $964,661	-336,119 Reduced 78.78%	90,533 $134,000
Q4 2022 Feb 10, 2023	BUY	$1.13 - $10.8 $473,236 - $4.52 Million	418,793 Added 5328.83%	426,652 $597,000
Q3 2022 Nov 14, 2022	BUY	$3.0 - $5.49 $8,538 - $15,624	2,846 Added 56.77%	7,859 $25,000
Q2 2022 Aug 12, 2022	SELL	$3.13 - $12.25 $11,493 - $44,982	-3,672 Reduced 42.28%	5,013 $17,000
Q1 2022 May 16, 2022	SELL	$9.54 - $14.26 $42,243 - $63,143	-4,428 Reduced 33.77%	8,685 $98,000
Q4 2021 Feb 08, 2022	BUY	$7.34 - $10.25 $50,469 - $70,479	6,876 Added 110.25%	13,113 $125,000
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $7,043 - $11,628	875 Added 16.32%	6,237 $54,000
Q2 2021 Sep 13, 2021	BUY	$11.76 - $16.85 $63,057 - $90,349	5,362 New	5,362 $65,000

Others Institutions Holding IMUX

# of Institutions

Shares Held

56.2M

Call Options Held

100

Put Options Held

350K

View Full List

About IMMUNIC, INC.

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $33M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

More about IMUX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Immunic, Inc. Transaction History